ArticleFrontiers in pharmacology2026
Metabolic remodeling and cardiac functional adaptation mediated by dapagliflozin in patients with acute heart failure: a retrospective cohort study.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims: Grounded in the "myocardial metabolic starvation" hypothesis, this study evaluated the pharmacological effects of dapagliflozin on serum metabolic profiles, ventricular remodeling, and cardiac function in patients hospitalized with acute heart failure (AHF), and explored the associations between circulating metabolic alterations, ventricular remodeling, and cardiac functional parameters. Methods: This single-center retrospective cohort study included 50 AHF patients (25 pairs) after 1:1 propensity score matching. The dapagliflozin group received standard care plus dapagliflozin 10 mg once daily for 6 months, while the control group received standard care alone. Changes in circulating metabolic parameters, including fasting blood glucose, lactic acid, free fatty acids, and ketone-related metabolites (β-hydroxybutyrate and acetoacetic acid), as well as glycolytic enzyme activity (pyruvate kinase), were compared between groups. Echocardiographic parameters, 6-min walk test (6 MWT) distance, B-type natriuretic peptide (BNP), and major adverse cardiovascular events (MACE) were also assessed. Results: The dapagliflozin group showed greater reductions in circulating metabolic parameters, particularly fasting plasma glucose, free fatty acids, β-hydroxybutyrate, and acetoacetic acid, compared with controls (all Conclusion: In this small retrospective cohort, early in-hospital initiation of dapagliflozin was associated with favorable changes in circulating metabolic profiles, ventricular remodeling, and cardiac function in patients with acute heart failure. These findings suggest potential therapeutic benefits for ventricular remodeling, but require confirmation in larger prospective studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.